Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2-Reference-Cited by-同舟云学术

Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2

Published:2017-05-23 Issue:9 Volume:89 Page:1567-1573
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

Watanabe Takao¹,Tokumoto Yoshio¹,Joko Kouji²,Michitaka Kojiro³,Horiike Norio⁴,Tanaka Yoshinori⁵,Tada Fujimasa⁶,Kisaka Yoshiyasu⁷,Nakanishi Seiji⁸,Nonaka Takashi⁹,Yamauchi Kazuhiko¹⁰,Hirooka Masashi¹,Abe Masanori¹,Hiasa Yoichi¹

Affiliation:

1. Department of Gastroenterology and Metabology; Ehime University Graduate School of Medicine; Toon Ehime Japan

2. Center for Liver-Biliary-Pancreatic Diseases; Matsuyama Red Cross Hospital; Matsuyama Ehime Japan

3. Department of Gastroenterology; Ehime Prefectural Central Hospital; Matsuyama Ehime Japan

4. Department of Gastroenterology; Saiseikai Imabari Hospital; Imabari Ehime Japan

5. Department of Gastroenterology; Matsuyama Shimin Hospital; Matsuyama Ehime Japan

6. Department of Internal Medicine; Saiseikai Matsuyama Hospital; Matsuyama Ehime Japan

7. Department of Gastroenterology; Uwajima City Hospital; Uwajima Ehime Japan

8. Department of Gastroenterology; Ehime Prefectural Imabari Hospital; Imabari Ehime Japan

9. Department of Internal Medicine; Ehime Prefectural Niihama Hospital; Niihama Ehime Japan

10. Department of Gastroenterology; National Hospital Organization Ehime Medical Center; Toon Ehime Japan

Publisher

Wiley

Subject

Infectious Diseases,Virology

Reference23 articles.

1. Novel therapies for hepatitis C-one pill fits all;Manns;Nat Rev Drug Discov,2013

2. Changing trends in hepatitis C infection over the past 50 years in Japan;Chung;Intervorology,2010

3. Changes in hepatitis C virus genotype distribution in Japan;Toyoda;Epidemiol Infect,2014

4. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses;Inoue;J Viral Hepat,2010

5. Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2;Kanda;Dig Dis Sci,2011

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients;Medicine;2023-07-14

2. Noninvasive assessments of liver disease severity based on biomarkers;Comprehensive Guide to Hepatitis Advances;2023

3. Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C;Biomedicines;2021-06-08

4. Liver fibrosis improvement assessed by magnetic resonance elastography and Mac‐2‐binding protein glycosylation isomer in patients with hepatitis C virus infection receiving direct‐acting antivirals;Hepatology Research;2021-03-16

5. Follow-up Results of HCV GT2 Patients After Sofosbuvir/Ribavirin Therapy: Careful Attention to Occurrence of HCC;Anticancer Research;2019-07